Full-Time

Territory Account Manager

Posted on 10/31/2025

Biomodal

Biomodal

51-200 employees

Hardware-agnostic multiomics sequencing for research

No salary listed

San Francisco, CA, USA

In Person

Category
Sales & Account Management (3)
, ,
Required Skills
Sales
Public Speaking
Hubspot
Marketing
Requirements
  • Bachelor’s degree in life sciences (e.g biology, molecular biology, etc)
  • Proven experience in Life Sciences sales/Account Management, preferably in NexGen Sequencing or multiomic technologies
  • Strong interpersonal, negotiation, and presentation skills.
  • Experience in CRM tools such as SFDC or HubSpot
  • Knowledge in the fields of cancer research, neuronal disorders, aging and/or reproductive health a plus
  • Must live on the West Coast, ideally with an understanding of the omics user base in that area
  • Exceptional communication skills in English – written and oral; must be a very strong public speaker.
  • Exceptional organizational skills – planning and follow through, track record of successfully managing many competing priorities at one time
  • Self-starter, solution oriented, collaborative, team-player; a “can-do” and “customer first” mentality
  • Glowing references for previous work in a relevant role - please be prepared to submit references that will be contacted by the hiring manager and HR.
Responsibilities
  • Manage and grow a portfolio of existing accounts within the assigned geography.
  • Identify, develop, and close new business opportunities to achieve sales targets.
  • Build and maintain strong relationships with key-decision makers and stakeholders.
  • Conduct regular customer visits to ensure customer satisfaction and identify upsell opportunities.
  • Develop a deep understanding of the customer’s needs and positions solutions to meet those needs
  • Work cross-functionally with internal teams (marketing, product, customer support) to ensure customer satisfaction.
  • Maintain accurate records of all sales activities in CRM software.
  • Attend industry events, trade shows and networking opportunities to build awareness
  • Develop, execute, monitor and report at an executive level, a commercial strategy to grow the territory
  • Develop and manage a growing opportunity pipeline and use CRM software effectively
  • Partner closely with marketing, customer solutions and executive team to evangelize the technology and develop customers advocates
  • Manage key accounts, KOLs and strategic collaborations to achieve commercial and corporate-level objectives
  • Average travel expectations: 50-60% time; mostly within North America but with the possibility to travel internationally if needed.
  • Other responsibilities TBD depending on the evolving needs of the company
Desired Qualifications
  • Knowledge in the fields of cancer research, neuronal disorders, aging and/or reproductive health a plus

Biomodal develops multiomics tools that analyze both genetic and epigenetic data from a single, small DNA sample using the duet multiomics platform. It reads the standard four DNA bases plus two modified bases (5mC and 5hmC) to produce a 6-base genome, with results fed through a software pipeline and compatible with existing sequencing machines. The approach is hardware-agnostic and provides a single workflow that covers genetics and epigenetics, unlike tools that focus on one aspect or require special instruments. Its goal is to equip life scientists and clinical developers with practical tools to accelerate biomarker discovery and research into cancer, neurodegenerative diseases, aging, and liquid biopsy applications.

Company Size

51-200

Company Stage

Series D

Total Funding

$185.1M

Headquarters

Cambridge, United Kingdom

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • duet evoC compatibility with Element AVITI boosts sensitivity in cancer and aging research.
  • Dennis Yuk Ming Lo joins scientific advisory board enhancing liquid biopsy expertise.
  • 95% bases above Q30 accuracy powers precise disease classifiers from limited samples.

What critics are saying

  • Illumina integrates native epigenetics into NovaSeq collapsing Biomodal's value in 12 months.
  • 10x Genomics Xenium expands spatial multiomics cannibalizing Biomodal's market in 6 months.
  • No Series E since 2021 depletes cash forcing dilutive financing in 12 months.

What makes Biomodal unique

  • Biomodal's duet evoC sequences 6-base genome distinguishing 5mC and 5hmC at single-base resolution.
  • Platform-agnostic duet integrates with existing sequencers for single-sample genetic-epigenetic analysis.
  • +modC enables low-volume cfDNA multiomics for cancer and neurodegenerative biomarker discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Paid Vacation

Performance Bonus

401(k) Retirement Plan

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

1%

2 year growth

3%
Business Wire
Feb 23rd, 2026
biomodal and Element Biosciences unite multiomic solutions with AVITI sequencing systems to accelerate clinical research

Biomodal, an omics-based life sciences technology company, has announced that its duet multiomic solutions are now compatible with Element Biosciences' AVITI24 5D multiomics and AVITI sequencing instruments. The integration, validated at the University of Minnesota Genomics Center, aims to enhance sensitivity for cancer, ageing and neurodegenerative disease research. The collaboration combines biomodal's 5-base and 6-base sequencing solutions with Element's sequencing systems, enabling complete methylation detection and delivering actionable insights within a single streamlined process. AVITI users gain access to biomodal's software pipeline, creating an end-to-end workflow for next-generation sequencing. Biomodal's platform-agnostic technology integrates pre-sequencing workflow with post-sequencing informatics to generate genetic and epigenetic data from a single sample in one run.

Business Wire
Feb 5th, 2024
Biomodal Delivers The 6-Base Genome With A Powerful New Multiomic Solution, Duet Evoc

CAMBRIDGE, England--(BUSINESS WIRE)--biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet evoC). The combinatorial genetic and epigenetic technology provides single-base-resolution sequencing data that reveals standard four-base sequencing (A, G, C, and T), and distinguishes between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), on the same DNA molecule. This added resolution will allow greater power in detecting disease associations, identifying novel biomarkers, developing disease classifiers, and monitoring the progression of disease; even with limited samples such as cell-free DNA (cfDNA). The advanced 6-base genome data enables the exploration of epigenetic mechanisms of gene regulation through methylation and hydroxymethylation. Researchers now are able to obtain an accurate measurement of 5mC and 5hmC, integrated into local genetic context, with 95% of bases above Q30 and 50% with accuracy above Q40. By measuring multiple modes of biology from a single low-input DNA sample in a single experiment, researchers can use the comprehensive data to build predictive models of gene expression, chromatin accessibility, and enhancer status to better understand the biological mechanisms that link genotype to phenotype

GenomeWeb
Apr 14th, 2023
People in the News at Adaptive Biotechnologies, Biocartis, Sherlock Biosciences, Epigenomics, More | GenomeWeb

Biomodal, formerly Cambridge Epigenetix, has appointed Dennis Yuk Ming Lo to its scientific advisory board and Omead Ostadan to its board of directors.

New Science Ventures
Jun 14th, 2022
Cambridge Epigenetix will hire Peter J. Fromen as Chief Executive Officer on Jul 18th 22'.

Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, has announced the appointment of Peter J. Fromen as Chief Executive Officer effective July 18, 2022.

Business Weekly
Nov 4th, 2021
Cambridge Epigenetix raises $88m in Series D round

Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising...

INACTIVE